相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series
Annabel McMillan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi
A. Broccoli et al.
BLOOD CANCER JOURNAL (2019)
Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience
Lisa Giulino-Roth et al.
LEUKEMIA & LYMPHOMA (2018)
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
Ann S. LaCasce et al.
BLOOD (2018)
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial
Owen A. O'Connor et al.
LANCET ONCOLOGY (2018)
Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial
Peter D. Cole et al.
LANCET ONCOLOGY (2018)
Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study
Franco Locatelli et al.
LANCET HAEMATOLOGY (2018)
Extended Follow-up of Patients Treated With Bendamustine for Lymphoid Malignancies
Mara Penne et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma
Peter Martin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study
Terzah M. Horton et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study
Alison J. Moskowitz et al.
LANCET ONCOLOGY (2015)
Ifosfamide and Vinorelbine Is an Effective Reinduction Regimen in Children With Refractory/Relapsed Hodgkin Lymphoma, AHOD00P1: A Children's Oncology Group Report
Tanya M. Trippett et al.
PEDIATRIC BLOOD & CANCER (2015)
Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi
Antonella Anastasia et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Declining Childhood and Adolescent Cancer Mortality
Malcolm A. Smith et al.
CANCER (2014)
Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate-Risk Hodgkin Lymphoma: A Report From the Children's Oncology Group Study AHOD0031
Debra L. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Stratification of Treatment Intensity in Relapsed Pediatric Hodgkin Lymphoma
Paul D. Harker-Murray et al.
PEDIATRIC BLOOD & CANCER (2014)
Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma
Gaetano Corazzelli et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma
Alison J. Moskowitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients
Herve Ghesquieres et al.
LEUKEMIA & LYMPHOMA (2013)
Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma
Craig H. Moskowitz et al.
BLOOD (2012)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma
Alison J. Moskowitz et al.
BLOOD (2010)
High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging
Craig H. Moskowitz et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425
Cindy L. Schwartz et al.
BLOOD (2009)
Phase II Study of Weekly Gemcitabine and Vinorelbine for Children With Recurrent or Refractory Hodgkin's Disease: A Children's Oncology Group Report
Peter D. Cole et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single-agent study
Jonathan W. Friedberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Salvage therapy of progressive and recurrent Hodgkin's disease:: Results from a multicenter study of the pediatric DAL/GPOH-HD study group
G Schellon et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: A Children's Cancer Group report
MS Cairo et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2001)
分享论文
